The FDA has approved Nuvation Bio’s oral medication Ibtrozi (taletrectinib) for treating ROS1-positive metastatic non-small cell lung cancer. Key clinical trials revealed strong response rates and prolonged durability of benefit, especially in patients without prior tyrosine kinase inhibitor exposure. This approval introduces a new therapy option in a lung cancer segment with existing multiple competitors, though safety warnings and market uncertainties remain.